5-HTP (5-Hydroxytryptophan)

Plain-language summaryIntrigue 55 / 100

5-HTP is the immediate precursor to serotonin, one biosynthetic step closer than tryptophan. Used as a supplement for mood and sleep. Combination with B6 increases conversion efficiency. Should not be combined with serotonergic medications. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

30/100

Well-understood serotonin precursor with modest clinical evidence and low research frontier value

Look, 5-HTP occupies a weird spot in the research landscape. It’s not junk. There are real clinical trials, some with reasonably controlled designs, showing signal in depression and sleep latency. But “not junk” doesn’t make something a compelling bench target in 2026, and thats essentially the problem here.

The mechanism is as simple as it gets. Tryptophan hydroxylase converts tryptophan to 5-HTP; aromatic L-amino acid decarboxylase converts 5-HTP to serotonin. That’s it. The one mechanistically interesting wrinkle, that 5-HTP bypasses large neutral amino acid competition at the BBB and gives more reliable CNS serotonin elevation than tryptophan itself, was characterized decades ago and is now textbook pharmacology. There’s nothing left to figure out here.

The differentiation problem is real. In any serious research program touching serotonergic pharmacology, you have access to direct 5-HT receptor subtype agonists with defined binding profiles, SERT inhibitors with well-characterized kinetics, and tryptophan depletion paradigms as a clean experimental control. 5-HTP sits in the middle of all of these: less clean than receptor-specific tools, less physiologically grounded than tryptophan loading, more variable than SSRIs. It’s not the sharpest tool for any one job.

What we don’t like: the clinical literature is old, scattered, and methodologically weak. The most-cited depression studies are 1970s and 1980s Italian trials with small N and questionable blinding. A Cochrane review called the evidence base insufficient, and that position hasn’t meaningfully changed. The headache and migraine prevention literature is similarly aged and underpowered. Nobody with serious resources is running 5-HTP RCTs right now, and that tells you something about where the field thinks the signal ends.

What we like, to the extent we can: 5-HTP has legitimate utility in serotonin depletion and repletion paradigms at the bench level, and for investigators studying the tryptophan-kynurenine-serotonin axis it’s a useful probe for isolating specific biosynthetic steps. The Griffonia simplicifolia extraction is well-characterized and sourcing is clean. These are minor credits, but they’re real.

Honestly, if your research touches serotonin biology in 2026, the more interesting territory is in 5-HT2A and 5-HT1A subtype pharmacology, the kynurenine pathway upstream, or novel psychoplastogen mechanisms. 5-HTP as a standalone compound answers a question that was already answered. We know it raises CNS serotonin. We know the downstream effects are real but modest and variable. The next question in this space requires different tools.

Novelty: 18
Mechanism promise: 22
In-category differentiation: 25
Evidence quality: 45
Translational signal: 45
Research bench value: 30

Rationale 5-HTP scores low on novelty and mechanism because the tryptophan-to-serotonin precursor chemistry is textbook pharmacology characterized decades ago; moderate evidence and translational scores reflect a real but methodologically weak clinical literature that hasn’t attracted serious new investment since the 1990s.

Serotonin precursor

5-Hydroxytryptophan, the immediate precursor of serotonin, derived from Griffonia simplicifolia seeds and used for mood and sleep applications.

Abstract

5-HTP (5-hydroxytryptophan; CAS 4350-09-8; molecular formula C11H12N2O3; molecular weight 220.23) is the immediate precursor of serotonin in the biosynthesis pathway from tryptophan. The compound is extracted from Griffonia simplicifolia seeds and sold as a dietary supplement. Unlike tryptophan, 5-HTP does not compete with other large neutral amino acids for transport into the CNS, providing more reliable elevation of central serotonin. The compound has been studied for depression, anxiety, sleep, and headache prevention. Use without a peripheral aromatic L-amino acid decarboxylase inhibitor produces peripheral serotonin elevation that may cause GI adverse events. Doses are typically 50 to 300 mg per day. Should not be combined with SSRIs or MAOIs due to serotonin syndrome risk.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-184Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.